Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Madmanmadoxon Feb 27, 2018 11:21pm

106 Views

Post# 27633758

RE:RE:RE:RE:RE:RE:RE:Financials are out in SEDAR; no News Release so far

Given the spam to yourself and your blind focus on Citagenix I hope you short this into March Phase 2 results. I have no problem taking more money from someone who so blindly promotes his own emotionally compromised position on the internet. I am betting you bought it back then at aquisition and sold it at 8 cents (when you first starting bashing it on Stockhouse) and missed the rally to 30 cents. No one is owning this company for Citagenix... except for maybe you... haha

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity